Business
Pipeline strategy and business update
Pipeline strategy and business update.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n 10 July 2023\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \n \nPipeline strategy and business update\n \n· Strategy to focus on development of Company's two lead clinical assets SCIB1 and Modi-1\n· Phase 2 SCOPE trial testing SCIB1 or iSCIB1+ in combination with checkpoint inhibitors in metastatic melanoma patients is progressing well with potential pathway for a registration trial\n· 44% disease control rate (DCR) in ovarian cancer patients in ModiFY monotherapy trial\n· Cash runway to 2H 2024 which covers near-term inflection points and cohort expansions\n \n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, provides an update on its two ongoing Phase 1/2 clinical trials with lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1. Encouraging data from these open label studies provides validation for the Company's decision to concentrate its strategic focus and resources on these two assets.\n \n\"I am very encouraged by the data we have seen so far from both the SCOPE trial with SCIB1 and the ModiFY trial with Modi-1, which support the decision to sharpen our focus on these two assets\" said Scancell CEO Lindy Durrant. \"With SCIB1 we have a clear potential development pathway involving a registration trial which could move this product rapidly towards the market. Additionally, I am pleased to see that Modi-1 is having an effect on disease control in ovarian cancer in these very heavily pre-treated patients, although we believe the true value of our vaccine is probably in combination with checkpoint inhibitors. We remain well positioned and funded to continue the development of these high-potential assets to the next near-term value inflection points.\"\n \nSCIB1/iSCIB1+\n \nThe open-label, Phase 2 single arm SCOPE trial is investigating the safety and tolerability of using SCIB1/iSCIB1+, Scancell's lead ImmunoBody® cancer vaccine, in combination with checkpoint inhibitors in patients with advanced melanoma. The current trial is designed to determine whether any clinical effect is unlikely to be due to checkpoints alone based on the rate of clinical responses in...